A case of localized peritoneal malignant mesothelioma with ovarian metastasis and literature review


  • Jingwen Wang Department of Gynecology, Third Affiliated Oriental Hepatobiliary Surgery Hospital, Naval Military Medical University, Shanghai, China
  • Rong Hu Department of Gynecology, Third Affiliated Oriental Hepatobiliary Surgery Hospital, Naval Military Medical University, Shanghai, China
  • Qian He Department of Gynecology, Third Affiliated Oriental Hepatobiliary Surgery Hospital, Naval Military Medical University, Shanghai, China




localized peritoneal malignant mesothelioma, ovarian tumor, diagnosis, case report


Peritoneal malignant mesothelioma (PMM) is a rare mesothelial cell-derived malignant tumor, which is clinically distinguished into a localized and diffuse forms, the latter being more common. The onset of PMM is insidious, so it is not easy to make a preoperative diagnosis of PMM. Clinicians must pay more attention to this disease in view of its poor prognosis. In order to improve the understanding of PMM, a case of patient with localized PMM metastasizing to the ovary is reported and discussed, along with a review of relevant literature to further explore the etiology, epidemiology, clinical manifestations, examination methods, diagnosis, treatment and prognosis of PMM.


Download data is not yet available.


Abbas H, Rodriguez JC, Tariq H, et al. Malignant peritoneal mesothelioma without asbestos exposure. Gastroenterology Res. 2019,12(1):48-51.

Chen R, Lou J, Zhang X. Guidelines for the pathological diagnosis of malignant mesothelioma -2012 up-date of the International Mesothelioma Interest Group Joint Statement. Chinese Journal of Industri-al Hygiene and Occupational Diseases, 2015,33(11):860-863.

Xi J, Hao J, Chen J. Research progress of peritoneal malignant mesothelioma. Contemp Med. 2020,26(25):192-194.

Husain AN, Colby TV, Ordόӣez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018,142(1):89-108.

Boussios S, Moschetta M, Karathanasi A, et al. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Ann Gastroenterol. 2018,31(6):659-669.

Chen K,Guo Z,Su D, et al. Epidemiology and clinical diagnosis and treatment of malignant mesothe-lioma in China. Chin J Thorac Cardiovasc Surg. 2017,33(7): 443-446.

Tanrikulu AC, AbakayA, Kaplan MA, et al. A clinical, radiographic and laboratory evaluation of prognos-tic factors in 363 patients with malignant pleural mesothelioma. Respiration. 2010,80(6):480 -487.

Deyin P. Diagnostic analysis of 236 cases with peritoneal mesothelioma in China. Chinese Oncology Clinic and Rehabilitation, 1996,3(2):73-75.

Chunlin Y. Combined detection of serum osteopontin and CA125 in 20 female patients with malignant peritoneal mesothelioma. Journal of Chinese Oncology. 2015,21(12):1019-1022.

Sun X, Zheng G, Liu C,et al. Ultrasound imaging analysis of diffuse malignant peritoneal mesothe-lioma. Clinical Focus. 2017, 32(4): 323-326.

Shang G,Wang X,Que Y,et al. Comparative analysis of ultrasound and CT in malignant peritoneal mesothelioma (report of 22 cases). Chinese J Ultrasound Med. 2016(7): 659-661.

Kato K, Gemba K, Fujimoto N, et al. Computed tomographic features of malignant peritoneal mesotheli-oma. Anticancer Res. 2016,36:1067-1072.

Tong R,Zeng Y,Yan Y, et al. Clinical analysis of 21 patients with peritoneal malignant mesothelioma. Acad J Chin PLA Med Sch Jan. 2016,37 (1):16-19.

Liu B, Zhou XJ. Pathological diagnosis of peritoneal malignant mesothelioma. J Diag Pathol. 2014,21(1):1-3.

Carbone M, Adusumilli PS, Alexander HR Jr, et al. Mesothelioma: Scientific clues for prevention, diagno-sis, and therapy. CA Cancer J Clin. 2019, 69(5):402-429.

Liu Y, Chen X, Ding N, et al. Detection of p16 by fluorescence in-situ hybridization and immuno-histochemistry in malignant mesothelioma. Chin J Pathol. 2015,44(4) :262-265.

Zhao Y, Feng R, Zeng X, et al. Malignant pleural mesothelioma:clinicopathologic analysis in a consecu-tive series of 64 patients from a single institution in China. Chin J Lung Dis. 2016,9(6):590-595.

Sun N,Zheng G,Song H, et al. Clinical analysis of dry-painful type malignant peritoneal mesothelioma. Clinical Focus. 2017,32(5):416.

Li Y,Zhou Y,Liang H, et al. Expert consensus on the treatment of peritoneal surface tumors by cell reduction combined with peritoneal thermoperfusion chemotherapy. Chin J Clin Oncol, 2015,42(4):198-206.

Cashin PH, Jansson PG, Asplund D, et al. Peritoneal mesothelioma in Sweden: A population based study. Cancer Med. 2019,8:6468-6475.

Shukuya T, Takahashi T, Imai H,et al. Comparison of cisplatin plus pemetrexed and cisplatin plus gem-citabine for the treatment of malignant pleural mesothelioma in Japanese patients. Respir Investig. 2014,52(2):101-106.

Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: a review. Transl Lung Cancer Res. 2018,7(5):537-542.

Li N, Chen Z, Mao W. Current status and progress on diagnosis and treatment of malignant peritoneal mesothelioma. Cancer Res Prev Treat. 2020,47(12):992-995.

Gudmundsson E, Labby Z, Straus CM, et al. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. Eur Radiol. 2019,29(2):682-688.

Alexander HR Jr, Li CY, Kennedy TJ. Current management and future opportunities for peritoneal metas-tases: peritoneal mesothelioma. Ann Surg Oncol. 2018, 25(8):2159-2164.

Liang Y,Zheng G,Li C, et al. Prognostic significance of COX-2,NF-KB,WT-1 and PTEN expression in malignant peritoneal mesothelioma. Cancer Res Prev Trea. 2016,43(8): 704-708.

Scattone A, Serio G, Marzullo A, et al. High Wilms′ tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma. Histopathology. 2012,60(3):472-481.






Case report